CCDC50 Knockout HAP1 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout population in HAP1 human haploid cells, designed to abrogate CCDC50 protein expression. This loss-of-function model enables systematic analysis of CCDC50??s inhibitory role in NF-??B and interferon signaling networks without the artifacts of clonal selection. The polyclonal format provides a heterogeneous allele pool well-suited for functional genomics, pathway interrogation, and drug discovery applications.
HAP1 cells are a near-haploid human male cell line derived from the KBM-7 chronic myeloid leukemia line, exhibiting an adherent fibroblast-like morphology. Their haploid karyotype simplifies CRISPR-mediated gene disruption and eliminates wild-type allele interference, making them a powerful platform for genetic screens, signal transduction studies, and knockout modeling. The CCDC50 knockout in this background offers a clean system to dissect negative regulatory mechanisms in immune signaling.
CCDC50 is an adaptor protein that negatively regulates NF-??B and interferon pathways by interacting with TRAF2, TRAF6, and IKBKG. It modulates the ubiquitination status of these factors, favoring signal-terminating ubiquitin modifications that restrain downstream kinase activation. Upon stimulation by TNF-??, IL-1, or Toll-like receptor ligands, CCDC50 suppresses TRAF6-mediated ubiquitin chain assembly, thereby limiting IKBKB activation and subsequent phosphorylation of I??B??. This restricts nuclear translocation of NFKB1/RELA dimers and dampens transcription of pro-inflammatory targets such as IL6 and TNFA, as well as interferon-stimulated genes. Knockout of CCDC50 removes this negative control, leading to sustained pathway activation and amplified immune gene expression.
In the HAP1 haploid background, CCDC50 disruption generates an unambiguous loss-of-function state, eliminating allelic compensation and enabling clear-cut dissection of negative feedback loops in NF-??B and interferon signaling. This model is particularly relevant for research into inflammatory diseases, hepatocellular carcinoma, and IgA nephropathy, where dysregulated immune pathways drive pathology. The polyclonal knockout population avoids clonal selection bias, better reflecting heterogeneous cellular responses and providing a robust platform for both mechanistic studies and high-throughput screening campaigns.
Researchers can employ these knockout cells in a variety of assays to monitor immune pathway activation: NF-??B luciferase reporter assays, Western blot analysis of phospho-I??B??, RT-qPCR quantification of NF-??B target genes (IL6, TNFA), and ISRE reporter assays for interferon signaling. Co-immunoprecipitation experiments can probe interactions between endogenous TRAF6 and ubiquitin ligases, while flow cytometry for phospho-STAT1 assesses interferon-driven responses. Functional phenotypes such as migration and invasion can be studied to link pathway activation to cellular behavior. These cells also serve as a high-signal screening tool for identifying small-molecule modulators of NF-??B or interferon pathways. For additional information, please contact Ascent Research.
